Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP logo The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States…


Register for upcoming October ACIP meeting

October 24-25, 2018


Deadline for registration:
Non-US Citizens: September 26, 2018
US Citizens: October 10, 2018

Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Live Webcast Instructions

Public Comment Instructions [1 page]

ACIP Recommendations

General Committee-related Information

  • Charter
    Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
  • Members
    Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
  • Articles
    Journal articles about the ACIP.


ACIP Flyer

ACIP brochure This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?

On November 9, 2017, FDA approved a new hepatitis B vaccine, HEPLISAV-B®, for use in adults 18 years of age and older.  HEPLISAV-B® is the first licensed vaccine using a CpG adjuvant* and is administered as two doses given one month apart.  Further details on this vaccine’s approval can be found at Vaccines Licensed for Use in the United States.

*Cytosine phosphoguanine (CpG) 1018 adjuvant

February 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its February 2018 meeting:

  • For the 2018-2019 influenza season, immunization providers are recommended to administer any licensed, age-appropriate influenza vaccine (IIV, RIV, or LAIV).  LAIV4 is an option for influenza vaccination for persons for whom it is otherwise appropriate.
  • HEPLISAV-B (HepB-CpG) is a Hepatitis B vaccine that may be used to vaccinate persons aged 18 years and older against infection caused by all known subtypes of hepatitis B virus.
  • Hepatitis A vaccines should be administered for post-exposure prophylaxis for all persons aged ≥12 months.
  • In addition to hepatitis A vaccine, immune globulin may be administered to persons aged >40 years depending on the providers’ risk assessment.
  • Hepatitis A vaccine should be administered to infants aged 6-11 months traveling outside the United States when protection against hepatitis A is recommended.
  • ACIP adopted an Evidence to Recommendation framework to support ACIP decision making.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

ACIP Meetings